UK price watchdog recommends against Amgen's Lumakras in lung cancer

July 9, 2026 01:52 PM EDT PharmaFDA+ UK price watch­dog rec­om­mends against Am­gen's Lumakras in lung can­cer Nicole DeFeudis Senior Reporter The UK’s drug pric­ing watch­dog said gov­ern­ment re­im­burse­ment of Am­gen’s lung can­cer drug Lumakras should be cut off for new pa­tients. In draft guid­ance re­leased … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER